The Amnesia Therapeutics Market is Forecast to Show Low Growth Until 2019

Friday 27 July 2012, Amsterdam

GlobalData, the industry analysis specialist, has released its new report, “Amnesia Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global amnesia market. The report identifies the key trends shaping and driving the global amnesia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global amnesia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The Amnesia Therapeutics Market is Forecast to Show Low Growth Until 2019

GlobalData estimates that the global amnesia therapeutics market was worth $112m in 2011, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.5% to reach $147m by 2019. This growth is primarily attributed to the increase in the general population and diagnosis rate across the seven major markets (the US, the UK, Japan, Germany, Spain, Italy and France).

Absence of Approved Therapies Leave a High Unmet Need in the Amnesia Therapeutics Market

GlobalData has found that the amnesia therapeutics market has a high level of unmet need as there are currently no approved therapies for treating amnesia. There are no approved drugs for the treatment of amnesia. Drugs such as benzodiazepines, Selective Serotonin Re-uptake Inhibitors (SSRIs) are commonly prescribed to address symptoms of anxiety and depression in amnesia patients. However, these drugs only focus on improving the patient’s Quality of Life (QoL) rather than treating of amnesia. This implies that there are opportunities available for new market entrants offering superior efficacy and safety for the treatment of amnesia.

Current Pipeline for Amnesia Therapeutics is Weak

GlobalData’s analysis shows that the current amnesia therapeutics pipeline is weak. The current amnesia therapeutics pipeline consists of only one molecule, levetiracetam, which is currently in Phase I of clinical development for the treatment of amnesia. There are no new molecules with novel mechanisms of action which are expected to enter the market during the forecast period.

The etiology and pathophysiology of amnesia is complex as it involves different causative factors as well as different mechanism pathways. This complex pathophysiology and etiology represents a challenging clinical development environment for market players and potential market entrants.